Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

Freiburg scientists discover substance that suppresses unchecked cell division in leukemia cells

Scientists of the University of Freiburg and the Freiburg University Medical Center from the collaborative research center Medical Epigenetics (SFB 992) have discovered a new active substance that inhibits cell division in leukemia cells and could play an important role in the fight against cancer.

27 Nov 2013

CSHL identifies specific stretch of DNA that helps cancerous blood cells to proliferate in AML

A team of researchers at Cold Spring Harbor Laboratory (CSHL) has identified a leukemia-specific stretch of DNA called an enhancer element that enables cancerous blood cells to proliferate in Acute Myeloid Leukemia (AML), a devastating cancer that is incurable in 70% of patients.

27 Nov 2013

Two separate studies yield key findings for prevention, diagnosis, treatment and cure for AML

26 Nov 2013

Researchers identify potential therapeutic target in treatment of certain AML

Acute myeloid leukemia (AML) is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase (HDAC) inhibitors, as potential candidates in the treatment of certain AML.

25 Nov 2013

Phase 1/2 clinical trial data for VAL-083 in glioblastoma is presented at 18th Annual SNO meeting

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced the presentation of interim data from a Phase 1/2 clinical trial for VAL-083 in recurrent glioblastoma (GBM) at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting in San Francisco.

25 Nov 2013

Research: Notch protein plays essential role in triggering T-cell development

The lab of Avinash Bhandoola, PhD, professor of Pathology and Laboratory Medicine, has studied the origins of T cells for many years. One protein called Notch, which has well-known roles in the development of multiple tissues, plays an essential role in triggering T-cell development.

25 Nov 2013

Scientists find link between airborne allergies and risk of blood cancers in women

A team of scientists looking into the interplay of the immune system and cancer have found a link between a history of airborne allergies - in particular to plants, grass and trees - with risk of blood cancers in women.

25 Nov 2013

Researchers discover new genetic risk factor for schizophrenia, bipolar disorder

Investigators at The Feinstein Institute for Medical Research have discovered a new genetic risk factor for schizophrenia and bipolar disorder called NDST3. The findings are published online in Nature Communications.

20 Nov 2013

Young adults who had childhood cancer more likely to be frail than their peers

Young adults who survived childhood cancer are more likely than their peers to be frail, according to a St. Jude Children's Research Hospital study, which reported the condition is more common among female survivors than women decades older. The research appears in the November 18 online edition of the Journal of Clinical Oncology.

18 Nov 2013

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.

18 Nov 2013

Childhood cancer survivors face heart problems decades after treatment

Cancer treatment takes a toll on the hearts of child survivors, according to research presented at the American Heart Association's Scientific Sessions 2013.

18 Nov 2013

GO drug may improve outcome of bone marrow transplantation for select pediatric leukemia patients

Combining the drug gemtuzumab ozogamicin with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia, according to a study led by St. Jude Children's Research Hospital. The results appear in the current edition of the journal Cancer.

16 Nov 2013

FDA approves ibrutinib for treatment of mantle cell lymphoma

Today's U.S. Food and Drug Administration approval of ibrutinib to treat patients with mantle cell lymphoma is a significant advance for patients with this blood cancer. It was approved as a single agent for treatment of patients with MCL who have received at least one prior therapy.

14 Nov 2013

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Cancer can be treated by a number of different ways depending on the location, grade and stage of tumour. A patient's age, medical history and lifestyle will also be taken into consideration and a combination of treatments will also be adopted to provide maximum effect.

14 Nov 2013

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

As of September 30, 2013, Delmar Pharmaceuticals has cash and equivalents of approximately $5.2 million and its working capital balance is in line with its expectations.

11 Nov 2013

Life-saving bone marrow transplants may also cure peanut allergies

Not only can bone marrow transplants be life-saving for children with acute lymphocytic leukemia, they may also cure peanut allergies. According to research presented during the American College of Allergy, Asthma and Immunology's Annual Scientific Meeting, a 10-year-old boy no longer had a peanut allergy after undergoing a bone marrow transplant.

8 Nov 2013

ImmunGene secures $9 million in Series A financing from Ally Bridge Group

ImmunGene, Inc., a biotechnology company focused on developing antibody-cytokine fusion technology therapies to treat cancer, today announced it has secured $9 million in a milestone-based Series A financing from Ally Bridge Group. Previous investments in the Company were converted into Series A preferred stock. ImmunGene will use the capital to advance its early-stage development products to IND-enabling studies.

7 Nov 2013

Majerus to donate $2M for new Primary Children's and Families' Cancer Research Center at HCI

Today the Majerus Family Foundation (a foundation Rick Majerus, former University of Utah basketball coach from 1989-2004, established prior to his death in 2012) announced that it will make a gift in the amount of $2 million toward the construction of the new Primary Children's and Families' Cancer Research Center at Huntsman Cancer Institute.

7 Nov 2013

Viewpoints: Obama's 'sin of omission;' Dems' panic grows over health law woes; men should pay for maternity care

"The big lie," as the president's broken Obamacare promise is now known, was that everyone could keep his or her doctor and insurance policy under the ACA. No one, Americans were justified in inferring, would be remotely inconvenienced by Obamacare. Instead, the reality is well-known: Millions are expected to lose their insurance policies, while others will see their premiums skyrocket. It is still jarring to my adult psyche to impugn another, especially the president of the United States, as a liar, so I won't. But it is not possible to pretend that the American people have been told the truth. Nor is it possible to pretend that Barack Obama has been completely honest (Kathleen Parker, 11/5).

7 Nov 2013

Leukemia News and Research

Further Reading

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Freiburg scientists discover substance that suppresses unchecked cell division in leukemia cells

CSHL identifies specific stretch of DNA that helps cancerous blood cells to proliferate in AML

Two separate studies yield key findings for prevention, diagnosis, treatment and cure for AML

Researchers identify potential therapeutic target in treatment of certain AML

Phase 1/2 clinical trial data for VAL-083 in glioblastoma is presented at 18th Annual SNO meeting

Research: Notch protein plays essential role in triggering T-cell development

Scientists find link between airborne allergies and risk of blood cancers in women

Researchers discover new genetic risk factor for schizophrenia, bipolar disorder

Young adults who had childhood cancer more likely to be frail than their peers

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Childhood cancer survivors face heart problems decades after treatment

GO drug may improve outcome of bone marrow transplantation for select pediatric leukemia patients

FDA approves ibrutinib for treatment of mantle cell lymphoma

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

Life-saving bone marrow transplants may also cure peanut allergies

ImmunGene secures $9 million in Series A financing from Ally Bridge Group

Majerus to donate $2M for new Primary Children's and Families' Cancer Research Center at HCI

Viewpoints: Obama's 'sin of omission;' Dems' panic grows over health law woes; men should pay for maternity care

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News